Form 4: Neumora Therapeutics CFO Sells Shares to Cover Tax Obligations

Michael Milligan, CFO of Neumora Therapeutics, sold 1,978 shares of common stock on February 18, 2025, to cover withholding obligations related to vesting restricted stock units.

Summary

• On February 18, 2025, Michael Milligan, the Chief Financial Officer of Neumora Therapeutics, sold 1,978 shares of the company's common stock.
• The sale was executed at a weighted average price of $1.6939 per share.
• The total number of shares beneficially owned by Milligan after the transaction is 22,470.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 30, 2024.
• The purpose of the sale was to satisfy withholding tax obligations associated with the vesting of restricted stock units.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction (sale of shares to cover tax obligations) and does not contain any information that would significantly impact investor sentiment positively or negatively.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Sales of shares to cover tax obligations are a common practice among corporate executives, particularly after the vesting of equity-based compensation.

Stakeholder Impact

• The sale of shares by the CFO could have a minor impact on shareholder perception, but is unlikely to be significant given the reason for the sale and the relatively small number of shares involved.

Key Dates

Keywords

Neumora Therapeutics, Michael Milligan, CFO, stock sale, Form 4, Rule 10b5-1, insider trading, NMRA, restricted stock units, withholding obligations